Innate immune cell and severe acute respiratory syndrome coronavirus 2 interaction

Abstract

Coronavirus disease caused by the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a major public health that has submerged the world into a crisis unprecedented in the modern era. A better understanding of the innate immune response could help to fight this pandemic and be better prepared for potential future outbreaks. Interestingly, innate immune cells can develop a non-specific memory termed trained immunity. This review details recent evidence concerning the interaction of SARS-CoV-2 with innate immune cells, in particular those in which the trained immunity activity has been demonstrated.

Keywords

Innate / immune / severe acute respiratory syndrome coronavirus 2 / productive infection

References

[1] Morse SS, Mazet JA, Woolhouse M, Parrish CR, Carroll D, Karesh WB, et al. Prediction and prevention of the next pandemic zoonosis. Lancet. 2012; 380: 1956-65.

[2] Trovato M, Sartorius R, D’pice L, Manco R, De Berardinis P. Viral emerging diseases: challenges in developing vaccination strategies. Front Immunol. 2020; 11: 2130.

[3] Tomalka JA, Suthar MS, Deeks SG, Sekaly RP. Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. Nat Immunol. 2022; 23: 360-70.

[4] Gasteiger G, D’Oaldo A, Schubert DA, Weber A, Bruscia EM, Hartl D. Cellular inate immunity: an old game with new players. J Innate Immun. 2017; 9: 111-25.

[5] Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. Nat Immunol. 2017; 18: 826-31.

[6] Jentho E, Weis S. DAMPs and innate immune training. Front Immunol. 2021; 12: 699563.

[7] Gardiner CM, Mills KH. The cells that mediate innate immune memory and their functional significance in inflammatory and infectious diseases. Semin Immunol. 2016; 28: 343-50.

[8] Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020; 20: 375-88.

[9] Cortes-Perez NG, de Moreno de LeBlanc A, Gomez-Gutierrez JG, LeBlanc JG, Bermudez-Humaran LG. Probiotics and trained immunity. Biomolecules. 2021; 11: 1402.

[10] Anderson HL, Brodsky IE, Mangalmurti NS. The evolving erythrocyte: red blood cells as modulators of innate immunity. J Immunol. 2018; 201: 1343-51.

[11] Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011; 9: 355-61.

[12] Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016; 352: aaf1098.

[13] Netea MG, van der Meer JW. Trained immunity: an ancient way of remembering. Cell Host Microbe. 2017; 21: 297-300.

[14] Fanucchi S, Domínguez-Andrés J, Joosten LAB, Netea MG, Mhlanga MM. The intersection of epigenetics and metabolism in trained immunity. Immunity. 2021; 54: 32-43.

[15] Zhou Z, Qiu Y, Ge X. The taxonomy, host range and pathogenicity of coronaviruses and other viruses in the Nidovirales order . Anim Dis. 2021; 1: 5.

[16] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536-44.

[17] V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021; 19: 155-70.

[18] Cavanagh D. The coronavirus surface glycoprotein. In: Siddell SG, editor. The coronaviridae. Boston, MA: Springer US; 1995. pp. 73-113.

[19] de Haan CA, Vennema H, Rottier PJ. Assembly of the coronavirus envelope: homotypic interactions between the M proteins. J Virol. 2000; 74: 4967-78.

[20] WHO coronavirus (COVID-19) dashboard [Internet]. Switzerland: World Health Organization ; [cited 2022 Apr 7]. Available from: https://covid19.who.int/

[21] Weekly epidemiological update on COVID-19 - 5 April 2022 [Internet]. Switzerland: World Health Organization; [cited 2022 Apr 7]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---5-april-2022

[22] Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022; 23: 165-76.

[23] Scudellari M. How the coronavirus infects cells - and why Delta is so dangerous. Nature. 2021; 595: 640-4.

[24] Mandala VS, McKay MJ, Shcherbakov AA, Dregni AJ, Kolocouris A, Hong M. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol. 2020; 27: 1202-8.

[25] Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Struct Mol Biol. 2022; 23: 3-20.

[26] Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020; 369: 330-3.

[27] Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020; 78: 779-84.e5.

[28] Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020; 117: 11727-34.

[29] Lavie M, Dubuisson J, Belouzard S. SARS-CoV-2 spike furin cleavage site and S2’ basic residues modulate the entry process in a host cell-dependent manner. J Virol. 2022; 96: e0047422.

[30] Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care. 2020; 24: 422.

[31] Zheng M. ACE2 and COVID-19 susceptibility and severity. Aging Dis. 2022; 13: 360-72.

[32] Acevedo OA, Berrios RV, Rodriguez-Guilarte L, Lillo-Dapremont B, Kalergis AM. Molecular and cellular mechanisms modulating trained immunity by various cell types in response to pathogen encounter. Front Immunol. 2021; 12: 745332.

[33] Rose M, Duhamel M, Rodet F, Salzet M. The role of proprotein convertases in the regulation of the function of immune cells in the oncoimmune response. Front Immunol. 2021; 12: 667850.

[34] You M, Chen L, Zhang D, Zhao P, Chen Z, Qin EQ, et al. Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19. Nat Cell Biol. 2021; 23: 620-30.

[35] Netea MG, Li Y. Immune memory in individuals with COVID-19. Nat Cell Biol. 2021; 23: 582-4.

[36] Lee JH, Koepke L, Kirchhoff F, Sparrer KMJ. Interferon antagonists encoded by SARS-CoV-2 at a glance. Med Microbiol Immunol. 2022;[Epub ahead of print].

[37] Kasuga Y, Zhu B, Jang KJ, Yoo JS. Innate immune sensing of coronavirus and viral evasion strategies. Exp Mol Med. 2021; 53: 723-36.

[38] Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun. 2020; 12: 4-20.

[39] Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021; 22: 829-38.

[40] Sariol A, Perlman S. SARS-CoV-2 takes its toll. Nat Immunol. 2021; 22: 801-2.

[41] Szabo MP, Iba M, Nath A, Masliah E, Kim C. Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Exp Mol Med. 2022; 54: 447-54.

[42] Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs . J Med Virol. 2020; 92: 2105-13.

[43] Kayesh MEH, Kohara M, Tsukiyama-Kohara K. An overview of recent insights into the response of TLR to SARS-CoV-2 infection and the potential of TLR agonists as SARS-CoV-2 vaccine adjuvants. Viruses. 2021; 13: 2302.

[44] Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediators Inflamm. 2021; 2021: 8874339.

[45] Mabrey FL, Morrell ED, Wurfel MM. TLRs in COVID-19: how they drive immunopathology and the rationale for modulation. Innate Immun. 2021; 27: 503-13.

[46] Patra R, Chandra Das N, Mukherjee S. Targeting human TLRs to combat COVID-19: a solution? J Med Virol. 2021; 93: 615-7.

[47] Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021; 31: 818-20. Erratum in: Cell Res. 2021; 31:825.

[48] Petruk G, Puthia M, Petrlova J, Samsudin F, Strömdahl AC, Cerps S, et al. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. J Mol Cell Biol. 2020; 12: 916-32.

[49] Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020; 5: 283.

[50] Geng JJ, Tang J, Yang XM, Chen R, Zhang Y, Zhang K, et al. Targeting CD147 for T to NK lineage reprogramming and tumor therapy. EBioMedicine. 2017; 20: 98-108.

[51] Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203: 631-7.

[52] Salamanna F, Maglio M, Landini MP, Fini M. Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2. Front Med (Lausanne). 2020; 7: 594495.

[53] Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19 . J Immunother Cancer. 2020; 8: e001020.

[54] Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. ; HCA Lung Biological Network. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020; 181: 1016-35.e19.

[55] Gorący A, Rosik J, Szostak B, Ustianowski Ł, Ustianowska K, Gorący J. Human cell organelles in SARS-CoV-2 infection: an up-to-date overview. Viruses. 2022; 14: 1092.

[56] Uhlen M, Karlsson MJ, Zhong W, Tebani A, Pou C, Mikes J, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science. 2019; 366: eaax9198.

[57] Elahi S. Hematopoietic responses to SARS-CoV-2 infection. Cell Mol Life Sci. 2022; 79: 187.

[58] Chen L, Ozato K. Innate immune memory in hematopoietic stem/progenitor cells: myeloid-biased differentiation and the role of interferon. Front Immunol. 2021; 12: 621333.

[59] Jalloh S, Olejnik J, Berrigan J, Nisa A, Suder EL, Akiyama H, et al. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. BioRxiv 486190 [Preprint]. 2022 [cited 2022 Mar 30]. Available from: https://www.biorxiv.org/content/10.1101/2022.03.29.486190v2

[60] Lempp FA, Soriaga LB, Montiel-Ruiz M, Benigni F, Noack J, Park YJ, et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature. 2021; 598: 342-7.

[61] Lu Q, Liu J, Zhao S, Gomez Castro MF, Laurent-Rolle M, Dong J, et al. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and tweety family member 2. Immunity. 2021; 54: 1304-19.e9.

[62] Onodi F, Bonnet-Madin L, Meertens L, Karpf L, Poirot J, Zhang SY, et al. SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4. J Exp Med. 2021; 218: e20201387.

[63] van der Sluis RM, Cham LB, Gris-Oliver A, Gammelgaard KR, Pedersen JG, Idorn M, et al. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. EMBO J. 2022; 41: e109622.

[64] Percivalle E, Sammartino JC, Cassaniti I, Arbustini E, Urtis M, Smirnova A, et al. Macrophages and monocytes: “Trojan horses” in COVID-19. Viruses. 2021; 13: 2178.

[65] Dalskov L, Møhlenberg M, Thyrsted J, Blay-Cadanet J, Poulsen ET, Folkersen BH, et al. SARS-CoV-2 evades immune detection in alveolar macrophages. EMBO Rep. 2020; 21: e51252.

[66] Tseng CT, Perrone LA, Zhu H, Makino S, Peters CJ. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005; 174: 7977-85.

[67] Boumaza A, Gay L, Mezouar S, Bestion E, Diallo AB, Michel M, et al. Monocytes and macrophages, targets of severe acute respiratory syndrome coronavirus 2: the clue for coronavirus disease 2019 immunoparalysis. J Infect Dis. 2021; 224: 395-406.

[68] Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020; 587: 657-62.

[69] Halim TY, Steer CA, Mathä L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014; 40: 425-35.

[70] Gomez-Cadena A, Spehner L, Kroemer M, Khelil MB, Bouiller K, Verdeil G, et al. Severe COVID-19 patients exhibit an ILC2 NKG2D⁺ population in their impaired ILC compartment . Cell Mol Immunol. 2021; 18: 484-6.

[71] Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004; 23: 255-9.

[72] Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol. 2022; 22: 112-23.

[73] Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021; 600: 295-301.

[74] Krämer B, Knoll R, Bonaguro L, ToVinh M, Raabe J, Astaburuaga-García R, et al.; Deutsche COVID-19 OMICS Initiative (DeCOI); Aschenbrenner AC, Schultze JL, Nattermann J. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021; 54: 2650-69.e14.

[75] Leem G, Cheon S, Lee H, Choi SJ, Jeong S, Kim ES, et al. Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J Allergy Clin Immunol. 2021; 148: 996-1006.e18.

[76] Kim H, Byun JE, Yoon SR, Koohy H, Jung H, Choi I. SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity. Cell Immunol. 2022; 371: 104454.

[77] Hammer Q, Dunst J, Christ W, Picarazzi F, Wendorff M, Momayyezi P, et al.; Karolinska COVID-19 Study Group, Severe COVID-19 GWAS Group; Degenhardt F, Franke A, Spallotta F, Mori M, Michaëlsson J, Björkström NK, et al. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. Cell Rep. 2022; 38: 110503.

[78] van Erp EA, van Kampen MR, van Kasteren PB, de Wit J. Viral infection of human natural killer cells. Viruses. 2019; 11: 243.

[79] Hazeldine J, Lord JM. Neutrophils and COVID-19: ative participants and rational therapeutic targets. Front Immunol. 2021; 12: 680134.

[80] Rawat S, Vrati S, Banerjee A. Neutrophils at the crossroads of acute viral infections and severity. Mol Aspects Med. 2021; 81: 100996.

[81] Veras FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, de Lima M, Nascimento DC, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med. 2020; 217: e20201129.

[82] Moreno-Eutimio MA, López-Macías C, Pastelin-Palacios R. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 2020; 22: 226-9.